re: Ann: Lead pain program to also target mor...
Finally, after 15 years of trying to get a deal going in the US and Europe, BLT have realised they have been concentrating on the wrong hemisphere. Time to employ an interpreter I think. China has $300 billion to spend on R&D and one of their main priorities is biotechnology. Meeting with the researchers at the university may be the foot in the door that BLT needs to get not just the pain program going, but the Hep B program as well.
BLT Price at posting:
50.0¢ Sentiment: Hold Disclosure: Held